Covid 19 Research using Clinical Trials (Home Page)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (2)
|
Name (Synonyms) |
Correlation |
drug232 | CELLECTRA® 2000 Wiki | 1.00 |
drug1200 | SF12, EQ-5D-5L and work status standardized quantitative assessments Wiki | 1.00 |
Correlated MeSH Terms (2)
|
Name (Synonyms) |
Correlation |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.06 |
D018352 | Coronavirus Infections NIH | 0.05 |
Correlated HPO Terms (0)
|
Name (Synonyms) |
Correlation |
There is one clinical trial.
Clinical Trials
This is an open-label trial to evaluate the safety, tolerability and immunological profile of
INO-4800 administered by intradermal (ID) injection followed by electroporation (EP) using
CELLECTRA® 2000 device in healthy adult volunteers.
Primary Outcomes
Measure: Percentage of Participants with Adverse Events (AEs) Time: Baseline up to Week 52
Measure: Percentage of Participants with Administration (Injection) Site Reactions Time: Day 0 up to Week 52
Measure: Percentage of Participants with Adverse Events of Special Interest (AESIs) Time: Baseline up to Week 52
Measure: Change from Baseline in Antigen-Specific Binding Antibody Titers Time: Baseline up to Week 52
Measure: Change from Baseline in Antigen-Specific Interferon-Gamma (IFN-γ) Cellular Immune Response Time: Baseline up to Week 52
No related HPO nodes (Using clinical trials)